Swine Flu Vaccination Market Report 2026

Swine Flu Vaccination Market Overview

• Swine Flu Vaccination market size has reached to $14.95 billion in 2025 • Expected to grow to $20.36 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Government Immunization Initiatives Impact On The Growth Of Influenza Vaccinations • Market Trend: Innovative Vaccine To Strengthen Position In Swine Flu Vaccination Market • North America was the largest region in 2025.

What Is Covered Under Swine Flu Vaccination Market?

Swine flu vaccination refers to vaccines designed to protect against the influenza viruses that commonly infect pigs (swine flu). The purpose of vaccines is to prevent transmission of swine flu from pigs to humans. The main vaccine types of the swine flu vaccination market are intranasal, toxoid, conjugate, inactivated vaccine, attenuated vaccine, and others. An intranasal vaccine is a type of vaccine that is administered through the nose. It stimulates the immune system to protect against specific diseases by introducing weakened or dead pathogens. The various treatment types include influenza, meningococcal, cervical cancer, pneumococcal, hepatitis, measles, mumps, and rubella and are used by various end users including hospitals, clinics, and others.

What Is The Swine Flu Vaccination Market Growth Forecast?

The swine flu vaccination market size is expected to see strong growth in the next few years. It will grow to $20.36 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing investments in pandemic preparedness, rising adoption of next-generation vaccine technologies, expansion of global vaccination coverage, growing emphasis on rapid-response immunization strategies, increased funding for infectious disease research. Major trends in the forecast period include increasing adoption of advanced influenza vaccine platforms, rising focus on zoonotic disease prevention, expansion of recombinant and dna-based vaccines, growing emphasis on rapid vaccine development cycles, enhanced cold chain and distribution capabilities.

What Is The Driver Of The Swine Flu Vaccination Market?

The government initiatives toward vaccination programs are expected to propel the growth of the swine flu vaccination market going forward. Government initiatives toward vaccination programs refer to policies and actions undertaken by governments to promote and facilitate vaccination campaigns. The swine flu vaccination incentivizes governments to prioritize immunization programs by providing necessary vaccines and resources to combat outbreaks effectively, bolstering public health initiatives. For instance, in September 2024, according to reports published by the Centers for Disease Control and Prevention, a US-based national public health agency responsible for controlling the introduction and spread of infectious diseases, during the 2023–24 flu season, 55.4% of children aged 6 months to 17 years received at least one dose of the flu vaccine. Also, the government has allocated 9.3 million doses of adult influenza vaccine to establish a stockpile in case of supply issues. Therefore, the increasing government initiatives toward vaccination programs are driving the growth of the swine flu vaccination industry.

Key Players In The Global Swine Flu Vaccination Market

Major companies operating in the swine flu vaccination market are Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, Moderna Inc., Serum Institute of India Private Limited, Bharat Biotech International Limited, Zoetis Inc., Elanco Animal Health, IDT Biologika GmbH, Vetoquinol SA, Medicago Inc., Panacea Biotec, Sinovac Biotech Ltd., Seqirus Pty Ltd, CSL Limited, Novavax Inc., Hualan Biological Engineering Inc., Valneva SE, Anhui Zhifei Longcom Biopharmaceutical Co Ltd, GSK Vaccines, AstraZeneca Plc, Sanofi Pasteur, Janssen Pharmaceuticals

Global Swine Flu Vaccination Market Trends and Insights

Major companies operating in the swine flu vaccination market are focused on developing innovative products such as the quadrivalent influenza vaccine, to strengthen their position in the market. A quadrivalent influenza vaccine is a type of flu vaccine designed to protect against four different influenza virus strains. For instance, in March 2024, Cadila Pharmaceuticals, an Indian-based pharmaceutical company, announced the launch of the cutting-edge quadrivalent influenza vaccine, Cadiflu Tetra, to prevent influenza. The Cadiflu Tetra Vaccine is a quadrivalent formulation targeting four influenza virus subtypes A and B strains. Its nano-sized particle technology mimics the virus's external structure, enhancing efficacy and safety without containing intact genetic material. This advanced approach improves protection against multiple influenza strains, offering a technologically superior solution for preventing seasonal epidemics.

What Are Latest Mergers And Acquisitions In The Swine Flu Vaccination Market?

In September 2024, Alopexx, Inc., a US-based clinical-stage biotechnology company, partnered with Bharat Biotech. The partnership aims to co-develop and commercialize Alopexx's broad-spectrum antimicrobial vaccine, AV0328, to address critical infectious disease needs in low- and middle-income countries, reducing antimicrobial resistance. This collaboration combines Bharat Biotech’s expertise in vaccine development with Alopexx’s innovative technology to make affordable, high-quality vaccines widely accessible. Bharat Biotech is an India-based manufacturer of swine flu vaccines.

What Defines the Swine Flu Vaccination Market?

The swine flu vaccination market includes revenues earned by entities by vaccine administration, assessment and screening, documentation and record-keeping, and follow-up and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The swine flu vaccination market consists of sales of fluMist quadrivalent, FluLaval quadrivalent, Fluzone quadrivalent, and afluria quadrivalent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Swine Flu Vaccination Market Report 2026?

The swine flu vaccination market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the swine flu vaccination industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.